Search company, investor...

Predict your next investment

Corporation
opko.com

Investments

10

Portfolio Exits

4

Partners & Customers

10

About OPKO Health

OPKO Health, formerly eXegenics, is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging discovery, development, and commercialization expertise. The company intends to leverage global commercialization expertise to pursue acquisitions of commercial businesses that will both drive growth and provide geographically diverse sales and distribution opportunities.

Headquarters Location

4400 Biscayne Blvd.

Miami, Florida, 33137,

United States

305-575-4100

Want to inform investors similar to OPKO Health about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing OPKO Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find OPKO Health in 3 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

H

Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Latest OPKO Health News

Prostate Cancer Diagnostics Market will achieve USD 11.16 billion by 2030 : GreyViews

Jan 17, 2023

Major Players MDXHEALTH, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Siemens Healthcare GmbH, Abbott, Metamark Genetics, Inc., HUMASIS, FUJIREBIO, OPKO Health, Inc., bioMérieux, Inc., Siemens Healthcare GmbH, Diasorin S.P.A. among others. Segmentation Analysis Preliminary is expected to be the fastest-growing segment in 2022. The test type segment includes confirmatory and preliminary. The preliminary segment is expected to witness the highest growth rate during the forecast period. As prostate cancer is on the rise over the forecast period in the region, it is boosting the demand for the preliminary test segment. The American Institute for Cancer Research has noted that PSA screening has helped diagnose and treat early cancers, leading to an increase in survival rates. PSA tests detect small, unrecognized tumours which may or may not progress to advanced stages. Hospital-associated laboratories are expected to be the fastest-growing segment in 2022. The end-user segment includes cancer research institutes, hospital-associated laboratories and independent diagnostics laboratories. The hospital-associated laboratories segment is expected to witness the highest growth rate during the forecast period. In the global prostate cancer diagnostics market, hospital associated laboratories are expected to take the majority share during the forecast period because of an increase in prostate cancer cases. In the forecast period, the market growth will be driven by rising disease prevalence and technological advancements. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the biomarkers market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. It is expected that North America will dominate the market due to factors such as increased prostate cancer prevalence, increased awareness, and the increasing number of research and development companies in this region. Prostate cancer cases are rising, creating huge opportunities for market players, and many are developing new and effective treatments. Country Analysis Germany Germany's prostate cancer diagnostics market size was valued at USD 0.83 billion in 2022 and is expected to reach USD 0.85 billion by 2030, at a CAGR of 13.5% from 2023 to 2030. Innovative products, growing awareness and government initiatives are all contributing to the growth of the prostate cancer diagnostics market. China China’s prostate cancer diagnostics market size was valued at USD 0.33 billion in 2022 and is expected to reach USD 0.92 billion by 2030, at a CAGR of 13.7% from 2023 to 2030. As China has a large population and therefore has more tests per capita than any other country in the region, China is expected to dominate the Asia-Pacific prostate cancer diagnostics market. India India's prostate cancer diagnostics market size was valued at USD 0.25 billion in 2022 and is expected to reach USD 0.69 billion by 2030, at a CAGR of 13.6% from 2023 to 2030. The availability of a wide range of products, adjustments in consumption patterns, improved lifestyles, and an increase in personal care spending are anticipated to contribute to the growth of the nail industry in the future. The popularity of nail polish and nail art has increased in the country due to a growing party culture as well as a variety of festivals and functions. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the increase due of the rising cases of cancer and cardiovascular diseases, propelling the growth of the market across the countries. Buy Now Full Report @ https://greyviews.com/checkout/334/single_user_license Contact Us

OPKO Health Investments

10 Investments

OPKO Health has made 10 investments. Their latest investment was in HealthSnap as part of their Series B on November 11, 2021.

CBI Logo

OPKO Health Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/12/2021

Series B

HealthSnap

$5M

Yes

2

8/2/2017

Series C

Eloxx Pharmaceuticals

$8M

No

2

6/26/2017

Series B - II

Eloxx Pharmaceuticals

$6M

Yes

1

8/23/2016

Corporate Minority

Subscribe to see more

Subscribe to see more

10

10/10/2013

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/12/2021

8/2/2017

6/26/2017

8/23/2016

10/10/2013

Round

Series B

Series C

Series B - II

Corporate Minority

Corporate Minority

Company

HealthSnap

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$5M

$8M

$6M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

OPKO Health Portfolio Exits

4 Portfolio Exits

OPKO Health has 4 portfolio exits. Their latest portfolio exit was Eloxx Pharmaceuticals on December 22, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/22/2017

Reverse Merger

$99M

2

8/23/2016

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

1/3/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2009

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/22/2017

8/23/2016

1/3/2014

7/15/2009

Exit

Reverse Merger

Reverse Merger

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

OPKO Health Acquisitions

16 Acquisitions

OPKO Health acquired 16 companies. Their latest acquisition was ModeX Therapeutics on May 09, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/9/2022

$99M

Acquired

2

6/30/2016

$99M

Acquired

1

5/5/2015

$99M

Acquired

2

5/22/2014

Subscribe to see more

$99M

Subscribe to see more

10

1/8/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/9/2022

6/30/2016

5/5/2015

5/22/2014

1/8/2014

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

OPKO Health Partners & Customers

10 Partners and customers

OPKO Health has 10 strategic partners and customers. OPKO Health recently partnered with Pfizer on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/15/2022

Licensee

United States

Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency.

In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of NGENLA for the treatment of GHD .

2

9/24/2021

Licensee

United States

News / Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency.

In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD .

2

9/14/2021

Licensee

United States

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories :: OPKO Health, Inc. (OPK)

SHANGHAI and MIAMI , Sept. 14 , 2021 -- LeaderMed Group , a pharmaceutical development company with operations based in Asia , and OPKO Health , Inc. , a diversified healthcare company focused on diagnostics and pharmaceuticals , announce the formation of a joint venture to develop , manufacture and commercialize two of OPKO Health , Inc. 's clinical stage , long-acting drug products in Greater China and eight other Asian territories .

1

8/12/2020

Client

United States

Subscribe to see more

Subscribe to see more

10

6/24/2020

Client

United States

Subscribe to see more

Subscribe to see more

10

Date

2/15/2022

9/24/2021

9/14/2021

8/12/2020

6/24/2020

Type

Licensee

Licensee

Licensee

Client

Client

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency.

In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of NGENLA for the treatment of GHD .

News / Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency.

In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD .

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories :: OPKO Health, Inc. (OPK)

SHANGHAI and MIAMI , Sept. 14 , 2021 -- LeaderMed Group , a pharmaceutical development company with operations based in Asia , and OPKO Health , Inc. , a diversified healthcare company focused on diagnostics and pharmaceuticals , announce the formation of a joint venture to develop , manufacture and commercialize two of OPKO Health , Inc. 's clinical stage , long-acting drug products in Greater China and eight other Asian territories .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

OPKO Health Team

11 Team Members

OPKO Health has 11 team members, including , .

Name

Work History

Title

Status

Michael Tolentino

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michael Tolentino

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.